Biomarker Guided Treatment in DLBCL
This study is to investigate the strategy of biomarker guided treatment in diffuse large B cell lymphoma
Diffuse Large B Cell Lymphoma
DRUG: Cyclophosphamide|DRUG: Rituximab|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisone|DRUG: Ibrutinib|DRUG: Lenalidomide|DRUG: chidamide|DRUG: decitabine
complete response rate, 21 days after 6 cycles of treatment (each cycle is 21 days)
progression free survival, 2 year|overall survival, 2 year|overall response rate, 21 days after 6 cycles of treatment (each cycle is 21 days)|Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0, Up to 30 days after completion of study treatment
This study is to investigate the strategy of biomarker guided treatment in diffuse large B cell lymphoma